Christopher Degnan
2022
In 2022, Christopher Degnan earned a total compensation of $834.9K as Chief Financial Officer at Galera Therapeutics, a 34% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $159,068 |
|---|---|
| Option Awards | $231,347 |
| Salary | $432,250 |
| Other | $12,200 |
| Total | $834,865 |
Degnan received $432.3K in salary, accounting for 52% of the total pay in 2022.
Degnan also received $159.1K in non-equity incentive plan, $231.3K in option awards and $12.2K in other compensation.
Rankings
In 2022, Christopher Degnan's compensation ranked 3,406th out of 5,760 executives tracked by ExecPay. In other words, Degnan earned more than 40.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,406 out of 5,760 | 41st |
Division Manufacturing | 1,928 out of 3,136 | 39th |
Major group Chemicals And Allied Products | 921 out of 1,422 | 35th |
Industry group Drugs | 861 out of 1,323 | 35th |
Industry Pharmaceutical Preparations | 627 out of 969 | 35th |
Source: SEC filing on April 27, 2023.
Degnan's colleagues
We found three more compensation records of executives who worked with Christopher Degnan at Galera Therapeutics in 2022.
News
Galera Therapeutics CEO J Sorensen's 2023 pay slips 8% to $1.3M
January 24, 2025
Galera Therapeutics CEO J Sorensen's 2022 pay falls 46% to $1.4M
April 27, 2023
Galera Therapeutics CEO J Sorensen's 2021 pay slips 14% to $2.5M
April 28, 2022
Galera Therapeutics CEO J Sorensen's 2019 pay jumps 373% to $2.5M
April 27, 2020